Search

Your search keyword '"Tomao, Federica"' showing total 635 results
Start Over Author "Tomao, Federica"
635 results on '"Tomao, Federica"'

7. Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer

Author

Colombo, Nicoletta, Tomao, Federica, Benedetti Panici, Pierluigi, Nicoletto, Maria Ornella, Tognon, Germana, Bologna, Alessandra, Lissoni, Andrea Alberto, DeCensi, Andrea, Lapresa, Mariateresa, Mancari, Rosanna, Palaia, Innocenza, Tasca, Giulia, Tettamanzi, Francesca, Alvisi, Maria Francesca, Rulli, Eliana, Poli, Davide, Carlucci, Luciano, Torri, Valter, Fossati, Roldano, and Biagioli, Elena

Published
2022
Full Text
View/download PDF

16. Hormone replacement therapy in gynecological cancer survivors and BRCA mutation carriers: a MITO group survey.

Author

Palaia, Innocenza, Caruso, Giuseppe, Di Donato, Violante, Turetta, Camilla, Savarese, Antonella, Perniola, Giorgia, Gallo, Roberta, Giannini, Andrea, Salutari, Vanda, Bogani, Giorgio, Tomao, Federica, Giannarelli, Diana, Gentile, Gabriella, Musella, Angela, Muzii, Ludovico, and Pignata, Sandro

Subjects
HORMONE therapy, CANCER survivors, MEDICAL personnel, BRCA genes, GYNECOLOGIC care, CANCER treatment
Abstract

Objective: Early iatrogenic menopause in gynecological cancer survivors and BRCA mutation (BRCAm) carriers undergoing risk-reducing salpingo-oophorectomy (RRSO) is a major health concern. Hormone replacement therapy (HRT) is the most effective remedy, but remains underused in clinical practice. The Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies (MITO) group promoted a national survey to investigate the knowledge and attitudes of healthcare professionals regarding the prescription of HRT. Methods: The survey consisted of a self-administered, multiple-choice 45-item questionnaire, available online to all MITO members for 2 months starting from January 2022. Results: A total of 61 participants completed the questionnaire (47 out of 180 MITO centers; compliance: 26.1%). Most respondents were female (73.8%), younger than 50 years (65.6%), and gynecologic oncologists (55.7%), working in public general hospitals (49.2%). An 84.4% of specialists actively discuss HRT with patients and 51.0% of patients ask the specialist for an opinion on HRT. The rate of specialists globally in favor of prescribing HRT was 22.9% for ovarian cancer, 49.1% for cervical cancer, and 8.2% for endometrial cancer patients. Most respondents (70.5%) believe HRT is safe for BRCA-mutated patients after RRSO. Nearly 70% of physicians prescribe systemic HRT, while 23.8% prefer local HRT. Most specialists recommend HRT for as long as there is a benefit and generally for up to 5 years. Conclusion: Real-world data suggest that many healthcare professionals still do not easily prescribe HRT for gynecological cancer survivors and BRCA mutation carriers after RRSO. Further efforts are required to implement the use of HRT in clinical practice and to support both clinicians in recommending HRT and patients in accepting it. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Imaging of Peritoneal Carcinomatosis in Advanced Ovarian Cancer: CT, MRI, Radiomic Features and Resectability Criteria

Author

Miceli, Valentina, primary, Gennarini, Marco, additional, Tomao, Federica, additional, Cupertino, Angelica, additional, Lombardo, Dario, additional, Palaia, Innocenza, additional, Curti, Federica, additional, Riccardi, Sandrine, additional, Ninkova, Roberta, additional, Maccioni, Francesca, additional, Ricci, Paolo, additional, Catalano, Carlo, additional, Rizzo, Stefania Maria Rita, additional, and Manganaro, Lucia, additional

Published
2023
Full Text
View/download PDF

21. Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study

Author

Colombo, Nicoletta, primary, Gadducci, Angiolo, additional, Landoni, Fabio, additional, Lorusso, Domenica, additional, Sabbatini, Roberto, additional, Artioli, Grazia, additional, Berardi, Rossana, additional, Ceccherini, Rita, additional, Cecere, Sabrina Chiara, additional, Cormio, Gennaro, additional, De Angelis, Carmine, additional, Legge, Francesco, additional, Lissoni, Andrea, additional, Mammoliti, Serafina, additional, Mangili, Giorgia, additional, Naglieri, Emanuele, additional, Petrella, Maria Cristina, additional, Ricciardi, Giuseppina Rosaria Rita, additional, Ronzino, Graziana, additional, Salutari, Vanda, additional, Sambataro, Daniela, additional, Savarese, Antonella, additional, Scandurra, Giuseppa, additional, Tasca, Giulia, additional, Tomao, Federica, additional, Valabrega, Giorgio, additional, Zavallone, Laura, additional, and Pignata, Sandro, additional

Published
2023
Full Text
View/download PDF

24. Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study

Author

Di Lisa, Francesca Sofia, primary, Krasniqi, Eriseld, additional, Pizzuti, Laura, additional, Barba, Maddalena, additional, Cannita, Katia, additional, De Giorgi, Ugo, additional, Borella, Fulvio, additional, Foglietta, Jennifer, additional, Cariello, Anna, additional, Ferro, Antonella, additional, Picardo, Elisa, additional, Mitidieri, Marco, additional, Sini, Valentina, additional, Stani, Simonetta, additional, Tonini, Giuseppe, additional, Santini, Daniele, additional, La Verde, Nicla, additional, Gambaro, Anna Rita, additional, Grassadonia, Antonino, additional, Tinari, Nicola, additional, Garrone, Ornella, additional, Sarobba, Giuseppina, additional, Livi, Lorenzo, additional, Meattini, Icro, additional, D’Auria, Giuliana, additional, Vergati, Matteo, additional, Gamucci, Teresa, additional, Pistelli, Mirco, additional, Berardi, Rossana, additional, Risi, Emanuela, additional, Giotta, Francesco, additional, Lorusso, Vito, additional, Rinaldi, Lucia, additional, Artale, Salvatore, additional, Cazzaniga, Marina Elena, additional, Zustovich, Fable, additional, Cappuzzo, Federico, additional, Landi, Lorenza, additional, Torrisi, Rosalba, additional, Scagnoli, Simone, additional, Botticelli, Andrea, additional, Michelotti, Andrea, additional, Fratini, Beatrice, additional, Saltarelli, Rosa, additional, Paris, Ida, additional, Muratore, Margherita, additional, Cassano, Alessandra, additional, Gianni, Lorenzo, additional, Gaspari, Valeria, additional, Veltri, Enzo Maria, additional, Zoratto, Federica, additional, Fiorio, Elena, additional, Fabbri, Maria Agnese, additional, Mazzotta, Marco, additional, Ruggeri, Enzo Maria, additional, Pedersini, Rebecca, additional, Valerio, Maria Rosaria, additional, Filomeno, Lorena, additional, Minelli, Mauro, additional, Scavina, Paola, additional, Raffaele, Mimma, additional, Astone, Antonio, additional, De Vita, Roy, additional, Pozzi, Marcello, additional, Riccardi, Ferdinando, additional, Greco, Filippo, additional, Moscetti, Luca, additional, Giordano, Monica, additional, Maugeri-Saccà, Marcello, additional, Zennaro, Alessandro, additional, Botti, Claudio, additional, Pelle, Fabio, additional, Cappelli, Sonia, additional, Cavicchi, Flavia, additional, Vizza, Enrico, additional, Sanguineti, Giuseppe, additional, Tomao, Federica, additional, Cortesi, Enrico, additional, Marchetti, Paolo, additional, Tomao, Silverio, additional, Speranza, Iolanda, additional, Sperduti, Isabella, additional, Ciliberto, Gennaro, additional, and Vici, Patrizia, additional

Published
2023
Full Text
View/download PDF

27. Poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer: lessons learned and future directions

Author

Caruso, G, Tomao, F, Parma, G, Lapresa, M, Multinu, F, Palaia, I, Aletti, G, Colombo, N, Caruso, Giuseppe, Tomao, Federica, Parma, Gabriella, Lapresa, Mariateresa, Multinu, Francesco, Palaia, Innocenza, Aletti, Giovanni, Colombo, Nicoletta, Caruso, G, Tomao, F, Parma, G, Lapresa, M, Multinu, F, Palaia, I, Aletti, G, Colombo, N, Caruso, Giuseppe, Tomao, Federica, Parma, Gabriella, Lapresa, Mariateresa, Multinu, Francesco, Palaia, Innocenza, Aletti, Giovanni, and Colombo, Nicoletta

Abstract

Poly (ADP-ribose) polymerase inhibitors (PARPi) represent a new standard of care in the upfront treatment of advanced epithelial ovarian cancer to the point that the vast majority of patients now receive a PARPi, alone or in combination with the anti-angiogenic bevacizumab, as part of their first-line maintenance therapy. The clinical benefit of PARPi is well established; however, much has changed since their introduction and several relevant questions have been raised and remain unresolved in the post-PARPi era. The decision-making process regarding the most appropriate first-line maintenance therapy could be challenging in clinical practice, especially in the homologous recombination-proficient setting, and several other factors need to be considered apart from the mutational status. Concerns regarding post-PARPi progression treatment have emerged, highlighting an unmet need to define a valid algorithm strategy. PARPi may not only compromise the response to further platinum due to cross-resistance mechanisms but the impact on subsequent non-platinum chemotherapy and surgery also remains unclear. Definitive results on the role of PARPi rechallenge are awaited, especially in the case of oligoprogression managed with locoregional treatment. Moreover, the updated overall survival data from the recurrent setting warrant caution in using PARPi as single agents for unselected patients. Several PARPi combination regimens are emerging for overcoming PARPi resistance and may become our new therapeutic armamentarium. This review discusses a set of clinically relevant issues in the PARPi era and provides a glimpse of future challenges and opportunities in ovarian cancer treatment.

Published
2023

28. Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study

Author

Colombo, N, Gadducci, A, Landoni, F, Lorusso, D, Sabbatini, R, Artioli, G, Berardi, R, Ceccherini, R, Cecere, S, Cormio, G, De Angelis, C, Legge, F, Lissoni, A, Mammoliti, S, Mangili, G, Naglieri, E, Petrella, M, Ricciardi, G, Ronzino, G, Salutari, V, Sambataro, D, Savarese, A, Scandurra, G, Tasca, G, Tomao, F, Valabrega, G, Zavallone, L, Pignata, S, Colombo, Nicoletta, Gadducci, Angiolo, Landoni, Fabio, Lorusso, Domenica, Sabbatini, Roberto, Artioli, Grazia, Berardi, Rossana, Ceccherini, Rita, Cecere, Sabrina Chiara, Cormio, Gennaro, De Angelis, Carmine, Legge, Francesco, Lissoni, Andrea, Mammoliti, Serafina, Mangili, Giorgia, Naglieri, Emanuele, Petrella, Maria Cristina, Ricciardi, Giuseppina Rosaria Rita, Ronzino, Graziana, Salutari, Vanda, Sambataro, Daniela, Savarese, Antonella, Scandurra, Giuseppa, Tasca, Giulia, Tomao, Federica, Valabrega, Giorgio, Zavallone, Laura, Pignata, Sandro, Colombo, N, Gadducci, A, Landoni, F, Lorusso, D, Sabbatini, R, Artioli, G, Berardi, R, Ceccherini, R, Cecere, S, Cormio, G, De Angelis, C, Legge, F, Lissoni, A, Mammoliti, S, Mangili, G, Naglieri, E, Petrella, M, Ricciardi, G, Ronzino, G, Salutari, V, Sambataro, D, Savarese, A, Scandurra, G, Tasca, G, Tomao, F, Valabrega, G, Zavallone, L, Pignata, S, Colombo, Nicoletta, Gadducci, Angiolo, Landoni, Fabio, Lorusso, Domenica, Sabbatini, Roberto, Artioli, Grazia, Berardi, Rossana, Ceccherini, Rita, Cecere, Sabrina Chiara, Cormio, Gennaro, De Angelis, Carmine, Legge, Francesco, Lissoni, Andrea, Mammoliti, Serafina, Mangili, Giorgia, Naglieri, Emanuele, Petrella, Maria Cristina, Ricciardi, Giuseppina Rosaria Rita, Ronzino, Graziana, Salutari, Vanda, Sambataro, Daniela, Savarese, Antonella, Scandurra, Giuseppa, Tasca, Giulia, Tomao, Federica, Valabrega, Giorgio, Zavallone, Laura, and Pignata, Sandro

Abstract

Introduction: Standard treatment of newly diagnosed, advanced ovarian carcinoma (OC) consists of cytoreductive surgery followed by platinum-based chemotherapy with or without bevacizumab. Maintenance therapy with PARP inhibitors and olaparib-bevacizumab has recently shown to significantly improve progression-free survival in the first-line setting. Some practical aspects of maintenance therapy, however, are still poorly defined. Aim of the study: To provide guidance to clinicians in the selection of maintenance therapy for newly diagnosed, advanced ovarian carcinoma. Methods: A board of six gynecologic oncologists with expertise in the treatment of OC in Italy convened to address issues related to the new options for maintenance treatment. Based on scientific evidences, the board produced practice-oriented statements. Consensus was reached via a modified Delphi study that involved a panel of 22 experts from across Italy. Results: Twenty-seven evidence- and consensus-based statements are presented, covering the following areas of interest: use of biomarkers (BRCA mutations and presence of homologous recombination deficiency); timing and outcomes of surgery; selection of patients eligible for bevacizumab; definition of response to treatment; toxicity and contraindications; evidence of synergy of bevacizumab plus PARP inhibitor. Two treatment algorithms are also included, for selecting maintenance therapy based on timing and outcomes of surgery, response to platinum-based chemotherapy and biomarker status. A score for the assessment of response to chemotherapy is proposed, but its validation is ongoing. Conclusions: We provide here consensus statements and treatment algorithms to guide clinicians in the selection of appropriate and personalized maintenance therapy in the first-line setting of advanced OC management.

Published
2023

29. Sexual dysfunctions in breast cancer patients: evidence in context

Author

Vizza, Riccardo, primary, Capomolla, Elisabetta Maria, additional, Tosetto, Livia, additional, Corrado, Giacomo, additional, Bruno, Valentina, additional, Chiofalo, Benito, additional, Di Lisa, Francesca Sofia, additional, Filomeno, Lorena, additional, Pizzuti, Laura, additional, Krasniqi, Eriseld, additional, Sanguineti, Giuseppe, additional, Villa, Alice, additional, Giannini, Andrea, additional, Kayal, Ramy, additional, Stranges, Vincenzo, additional, Tomao, Silverio, additional, Botti, Claudio, additional, Tomao, Federica, additional, Barba, Maddalena, additional, Vizza, Enrico, additional, Ciliberto, Gennaro, additional, and Vici, Patrizia, additional

Published
2023
Full Text
View/download PDF

30. Supplementary Figure 1 from Inhibition of Tumor Growth and Angiogenesis by SP-2, an Anti–Lectin, Galactoside-Binding Soluble 3 Binding Protein (LGALS3BP) Antibody

Author

Traini, Sara, primary, Piccolo, Enza, primary, Tinari, Nicola, primary, Rossi, Cosmo, primary, La Sorda, Rossana, primary, Spinella, Francesca, primary, Bagnato, Anna, primary, Lattanzio, Rossano, primary, D'Egidio, Maurizia, primary, Di Risio, Annalisa, primary, Tomao, Federica, primary, Grassadonia, Antonino, primary, Piantelli, Mauro, primary, Natoli, Clara, primary, and Iacobelli, Stefano, primary

Published
2023
Full Text
View/download PDF

31. Supplementary Figure Legend from Inhibition of Tumor Growth and Angiogenesis by SP-2, an Anti–Lectin, Galactoside-Binding Soluble 3 Binding Protein (LGALS3BP) Antibody

Author

Traini, Sara, primary, Piccolo, Enza, primary, Tinari, Nicola, primary, Rossi, Cosmo, primary, La Sorda, Rossana, primary, Spinella, Francesca, primary, Bagnato, Anna, primary, Lattanzio, Rossano, primary, D'Egidio, Maurizia, primary, Di Risio, Annalisa, primary, Tomao, Federica, primary, Grassadonia, Antonino, primary, Piantelli, Mauro, primary, Natoli, Clara, primary, and Iacobelli, Stefano, primary

Published
2023
Full Text
View/download PDF

32. Role of Genomic and Molecular Biology in the Modulation of the Treatment of Endometrial Cancer: Narrative Review and Perspectives

Author

Cuccu, Ilaria, primary, D’Oria, Ottavia, additional, Sgamba, Ludovica, additional, De Angelis, Emanuele, additional, Golia D’Augè, Tullio, additional, Turetta, Camilla, additional, Di Dio, Camilla, additional, Scudo, Maria, additional, Bogani, Giorgio, additional, Di Donato, Violante, additional, Palaia, Innocenza, additional, Perniola, Giorgia, additional, Tomao, Federica, additional, Muzii, Ludovico, additional, and Giannini, Andrea, additional

Published
2023
Full Text
View/download PDF

34. Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study

Author

Colombo, Nicoletta, Gadducci, Angiolo, Landoni, Fabio, Lorusso, Domenica, Sabbatini, Roberto, Artioli, Grazia, Berardi, Rossana, Ceccherini, Rita, Cecere, Sabrina Chiara, Cormio, Gennaro, De Angelis, Carmine, Legge, Francesco, Lissoni, Andrea, Mammoliti, Serafina, Mangili, Giorgia, Naglieri, Emanuele, Petrella, Maria Cristina, Ricciardi, Giuseppina Rosaria Rita, Ronzino, Graziana, Salutari, Vanda, Sambataro, Daniela, Savarese, Antonella, Scandurra, Giuseppa, Tasca, Giulia, Tomao, Federica, Valabrega, Giorgio, Zavallone, Laura, Pignata, Sandro, Colombo, N, Gadducci, A, Landoni, F, Lorusso, D, Sabbatini, R, Artioli, G, Berardi, R, Ceccherini, R, Cecere, S, Cormio, G, De Angelis, C, Legge, F, Lissoni, A, Mammoliti, S, Mangili, G, Naglieri, E, Petrella, M, Ricciardi, G, Ronzino, G, Salutari, V, Sambataro, D, Savarese, A, Scandurra, G, Tasca, G, Tomao, F, Valabrega, G, Zavallone, L, and Pignata, S

Subjects
Bevacizumab, Olaparib, PARP inhibitor, HRD, Advanced ovarian cancer, BRCA, Maintenance therapy, Niraparib
Abstract

Introduction: Standard treatment of newly diagnosed, advanced ovarian carcinoma (OC) consists of cytoreductive surgery followed by platinum-based chemotherapy with or without bevacizumab. Maintenance therapy with PARP inhibitors and olaparib-bevacizumab has recently shown to significantly improve progression-free survival in the first-line setting. Some practical aspects of maintenance therapy, however, are still poorly defined. Aim of the study: To provide guidance to clinicians in the selection of maintenance therapy for newly diagnosed, advanced ovarian carcinoma. Methods: A board of six gynecologic oncologists with expertise in the treatment of OC in Italy convened to address issues related to the new options for maintenance treatment. Based on scientific evidences, the board produced practice-oriented statements. Consensus was reached via a modified Delphi study that involved a panel of 22 experts from across Italy. Results: Twenty-seven evidence- and consensus-based statements are presented, covering the following areas of interest: use of biomarkers (BRCA mutations and presence of homologous recombination deficiency); timing and outcomes of surgery; selection of patients eligible for bevacizumab; definition of response to treatment; toxicity and contraindications; evidence of synergy of bevacizumab plus PARP inhibitor. Two treatment algorithms are also included, for selecting maintenance therapy based on timing and outcomes of surgery, response to platinum-based chemotherapy and biomarker status. A score for the assessment of response to chemotherapy is proposed, but its validation is ongoing. Conclusions: We provide here consensus statements and treatment algorithms to guide clinicians in the selection of appropriate and personalized maintenance therapy in the first-line setting of advanced OC management.

Published
2023

35. Advances in small molecule maintenance therapies for high-grade serous ovarian cancer

Author

Fischetti, Margherita, primary, Di Donato, Violante, additional, Palaia, Innocenza, additional, Perniola, Giorgia, additional, Tomao, Federica, additional, Perrone, Chiara, additional, Giancotti, Antonella, additional, Di Mascio, Daniele, additional, Monti, Marco, additional, Muzii, Ludovico, additional, Benedetti Panici, Pierluigi, additional, and Bogani, Giorgio, additional

Published
2022
Full Text
View/download PDF

36. MRI- and Histologic-Molecular-Based Radio-Genomics Nomogram for Preoperative Assessment of Risk Classes in Endometrial Cancer

Author

Celli, Veronica, primary, Guerreri, Michele, additional, Pernazza, Angelina, additional, Cuccu, Ilaria, additional, Palaia, Innocenza, additional, Tomao, Federica, additional, Di Donato, Violante, additional, Pricolo, Paola, additional, Ercolani, Giada, additional, Ciulla, Sandra, additional, Colombo, Nicoletta, additional, Leopizzi, Martina, additional, Di Maio, Valeria, additional, Faiella, Eliodoro, additional, Santucci, Domiziana, additional, Soda, Paolo, additional, Cordelli, Ermanno, additional, Perniola, Giorgia, additional, Gui, Benedetta, additional, Rizzo, Stefania, additional, Della Rocca, Carlo, additional, Petralia, Giuseppe, additional, Catalano, Carlo, additional, and Manganaro, Lucia, additional

Published
2022
Full Text
View/download PDF

40. An update on current pharmacotherapy for vulvar cancer

Author

Bogani, Giorgio, primary, Palaia, Innocenza, additional, Perniola, Giorgia, additional, Tomao, Federica, additional, Giancotti, Antonella, additional, Di Mascio, Daniele, additional, Capalbo, Giuseppe, additional, Muzii, Ludovico, additional, Benedetti Panici, Pierluigi, additional, and Di Donato, Violante, additional

Published
2022
Full Text
View/download PDF

46. CT-Based Radiomics and Deep Learning for BRCA Mutation and Progression-Free Survival Prediction in Ovarian Cancer Using a Multicentric Dataset

Author

Avesani, Giacomo, primary, Tran, Huong Elena, additional, Cammarata, Giulio, additional, Botta, Francesca, additional, Raimondi, Sara, additional, Russo, Luca, additional, Persiani, Salvatore, additional, Bonatti, Matteo, additional, Tagliaferri, Tiziana, additional, Dolciami, Miriam, additional, Celli, Veronica, additional, Boldrini, Luca, additional, Lenkowicz, Jacopo, additional, Pricolo, Paola, additional, Tomao, Federica, additional, Rizzo, Stefania Maria Rita, additional, Colombo, Nicoletta, additional, Manganaro, Lucia, additional, Fagotti, Anna, additional, Scambia, Giovanni, additional, Gui, Benedetta, additional, and Manfredi, Riccardo, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results